J. Malik

发表

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

J. Larkin, M. Atkins, A. Poprach, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre

M. Stares, T. Elliott, V. Chauhan, 2022, Cancer Medicine.

A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)

James O. Jones, A. Matakidou, E. Sala, 2022, British Journal of Cancer.

Five‐year outcomes after iodine‐125 seed brachytherapy for low‐risk prostate cancer at three cancer centres in the UK

P. Hoskin, J. Logue, D. Bottomley, 2014, BJU international.

Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapy.

J. Logue, C. Taylor, T. Elliott, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.

J. Larkin, M. Atkins, V. Matveev, 2018 .

KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC).

J. Larkin, M. Atkins, V. Matveev, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A megavoltage scatter correction technique for cone-beam CT images acquired during VMAT delivery

C G Rowbottom, T. Marchant, C. Rowbottom, 2012, Physics in medicine and biology.

NAXIVA: A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer (RCC) with venous invasion.

F. Gallagher, S. Welsh, I. Mendichovszky, 2021 .

Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.

S. Signoretti, J. Larkin, M. Atkins, 2020 .

The Importance of Prostate-specific Antigen (PSA) Nadir and Early Identification of PSA Relapse after 10 Years of Prostate Iodine 125 Seed Brachytherapy in Edinburgh.

A. Law, J. Brush, J. Keanie, 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

Challenging Presentations of Germ Cell Tumours in Routine Clinical Practice

Jeff White, N. Bezawada, A. Waterston, 2021, The journal of the Royal College of Physicians of Edinburgh.

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.

M. Atkins, A. Poprach, D. Cho, 2020, Journal of Clinical Oncology.

First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.

M. Atkins, A. Poprach, D. Cho, 2020 .

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A

V. Matveev, M. B. Atkins, C. Szczylik, 2019, Annals of Oncology.